C. Baccan

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

M. Kudo, A. Santoro, A. El-Khoueiry, 2019, Journal of Clinical Oncology.

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

M. Kudo, A. Santoro, F. Costanzo, 2019, Journal of Clinical Oncology.

Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040

J. Furuse, G. Abou-Alfa, R. Finn, 2019, Clinical research.